Kernal Biologics, based in Cambridge, MA, specializes in developing onco-selective mRNA therapeutics. The company operates in the biotechnology sector, focusing on creating advanced treatments for cancer and infectious diseases like COVID-19. Kernal Biologics serves healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around leveraging proprietary design and manufacturing processes to produce mRNA therapies that evade RNA sensors and enable cell-specific therapeutic protein expression. This approach aims to make treatments more effective, tolerable, and affordable. Revenue is generated through partnerships, grants, and sales of its mRNA platforms and therapies. The company has received multiple awards, including Amgen's Golden Ticket, and is recognized for its innovative use of synthetic biology and deep learning algorithms to enhance mRNA design.

Keywords: mRNA therapeutics, onco-selective, synthetic biology, deep learning, cancer treatment, COVID-19, immunotherapy, biotechnology, proprietary platform, cell-specific.